Thromboembolic and bleeding complications in patients with oesophageal cancer.

ABSTRACT:

Background

In patients who undergo curative treatment for oesophageal cancer, risk estimates of venous thromboembolism (VTE), arterial thromboembolism and bleeding are needed to guide decisions about thromboprophylaxis.

Methods

This was a single-centre, retrospective cohort study of patients with stage I-III oesophageal cancer who received neoadjuvant chemoradiation followed by oesophagectomy. The outcomes VTE, arterial thromboembolism, major bleeding, clinically relevant non-major bleeding and mortality were analysed for four consecutive cancer treatment stages (from diagnosis to neoadjuvant chemoradiotherapy, during neoadjuvant treatment, 30-day postoperative period, and up to 6 months after postoperative period).

Results

Some 511 patients were included. The 2-year

SUBMITTER: Mulder FI 

PROVIDER: S-EPMC7497123 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature